Curis share price today
(NASDAQ: CRIS)

Name: Curis Share Price Today (NASDAQ: CRIS) - Curis Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Curis share price is $3.27 & ₹282.82 as on 23 Jan 2025, 20.22 hrs IST

$3.27

▲

-0.16

(-4.66%)

Market is closed - opens 8 PM, 23 Jan 2025

View live Curis share price in Dollar and Rupees. Guide to invest in Curis stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Curis, along with analyst recommendations, forecasts, and comprehensive financials.

Curis share price movements

Today's Low: $3.19
Today's High: $3.42
$3.27
2.45%
Downside
Day's Volatility :6.68%
Upside
4.34%
52 Weeks Low: $2.86
52 Weeks High: $17.49
$3.27
12.54%
Downside
52 Weeks Volatility :83.65%
Upside
81.3%

Curis Returns

Period	Curis Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-36.75%	-5.5%	0.0%
6 Months	-45.68%	-4.3%	0.0%
1 Year	-64.07%	1.6%	0.0%
3 Years	-95.0%	9.8%	-11.0%

Curis Key Statistics

in dollars & INR

Previous Close	$3.27
Open	$3.38
Today's High	$3.3528
Today's Low	$3.27
Market Capitalization	$27.7M
Today's Volume	$39.1K
52 Week High	$17.49
52 Week Low	$2.86
Revenue TTM	$10.2M
EBITDA	$-49.3M
Earnings Per Share (EPS)	$-7.77
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-372.68%

How to invest in Curis Stock (CRIS) from India?

It is very easy for Indian residents to invest directly in Curis from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Curis stock in both Indian Rupees (INR) and US Dollars (USD). Search for Curis or CRIS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Curis or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Curis shares which would translate to 0.264 fractional shares of Curis as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Curis, in just a few clicks!

Returns in Curis for Indian investors in Rupees

Investment Value

₹1,00,000

Curis investment value today

Current value as on today

₹39,988

Returns

₹60,012

(-60.01%)

Returns from Curis Stock

₹64,066 (-64.07%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Curis

283%

Period: Oct 24, 2024 to Jan 22, 2025. Change in 30 Days versus previous period

Search volume for Curis on INDmoney from India has grown in the last 30 days as on Jan 23, 2025. 283% more investors are searching Curis in the last 30 days versus the previous period.

Global Institutional Holdings in Curis

Maverick Capital Ltd
6.88%
M28 Capital Management LP
4.98%
Vanguard Group Inc
3.24%
CM Management, LLC
1.42%
Renaissance Technologies Corp
1.11%
Citigroup Inc
1.09%

Analyst Recommendation on Curis

Buy

83%Buy

16%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Curis(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Curis

What analysts predicted

Upside of 542.2%

Target:

$21.00

Current:

$3.27

Insights on Curis

Price Movement
In the last 3 months, CRIS stock has moved down by -37.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 2.08M → 2.93M (in $), with an average increase of 15.6% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -11.87M → -10.09M (in $), with an average increase of 8.8% per quarter
CRIS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 111.6%
CRIS vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 190.1%
Price to Sales
ForCRIS every $1 of sales, investors are willing to pay $1.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.1 for every $1 of sales.

Curis Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$10.4M	↑ 5.35%
Net Income	$-32.6M	↓ 38.9%
Net Profit Margin	-312.38%	↑ 226.28%

	FY19	Y/Y Change
Revenue	$10.0M	↓ 4.07%
Net Income	$-36.8M	↑ 12.98%
Net Profit Margin	-367.89%	↓ 55.51%

	FY20	Y/Y Change
Revenue	$10.8M	↑ 8.31%
Net Income	$-34.9M	↓ 5.22%
Net Profit Margin	-321.93%	↑ 45.96%

	FY21	Y/Y Change
Revenue	$10.6M	↓ 1.72%
Net Income	$-50.6M	↑ 45.18%
Net Profit Margin	-475.54%	↓ 153.61%

	FY22	Y/Y Change
Revenue	$10.2M	↓ 4.57%
Net Income	$-60.3M	↑ 19.12%
Net Profit Margin	-593.62%	↓ 118.08%

	FY23	Y/Y Change
Revenue	$10.0M	↓ 1.37%
Net Income	$-47.4M	↓ 21.4%
Net Profit Margin	-473.04%	↑ 120.58%

	Q2 FY23	Q/Q Change
Revenue	$2.2M	↓ 4.35%
Net Income	$-12.0M	↑ 4.09%
Net Profit Margin	-544.42%	↓ 44.16%

	Q3 FY23	Q/Q Change
Revenue	$2.8M	↑ 28.95%
Net Income	$-12.2M	↑ 1.84%
Net Profit Margin	-429.97%	↑ 114.45%

	Q4 FY23	Q/Q Change
Revenue	$2.7M	↓ 4.84%
Net Income	$-11.8M	↓ 3.29%
Net Profit Margin	-436.94%	↓ 6.97%

	Q1 FY24	Q/Q Change
Revenue	$2.1M	↓ 22.63%
Net Income	$-11.9M	↑ 0.81%
Net Profit Margin	-569.32%	↓ 132.38%

	Q2 FY24	Q/Q Change
Revenue	$2.5M	↑ 22.05%
Net Income	$-11.8M	↓ 0.61%
Net Profit Margin	-463.59%	↑ 105.73%

	Q3 FY24	Q/Q Change
Revenue	$2.9M	↑ 15.12%
Net Income	$-10.1M	↓ 14.5%
Net Profit Margin	-344.32%	↑ 119.27%

	FY18	Y/Y Change
Profit	$9.9M	↑ 4.92%

	FY19	Y/Y Change
Profit	$9.5M	↓ 3.69%

	FY20	Y/Y Change
Profit	$10.3M	↑ 8.42%

	FY21	Y/Y Change
Profit	$10.1M	↓ 1.8%

	FY22	Y/Y Change
Profit	$9.9M	↓ 2.09%

	FY23	Y/Y Change
Profit	$10.0M	↑ 1.19%

	Q2 FY23	Q/Q Change
Profit	$2.1M	↓ 6.6%

	Q3 FY23	Q/Q Change
Profit	$2.8M	↑ 30.62%

	Q4 FY23	Q/Q Change
Profit	$2.5M	↓ 8.47%

	Q1 FY24	Q/Q Change
Profit	$1.6M	↓ 36.13%

	Q2 FY24	Q/Q Change
Profit	$2.5M	↑ 56.32%

	Q3 FY24	Q/Q Change
Profit	$2.9M	↑ 14.8%

	FY18	Y/Y Change
Operating Cash Flow	$-30.1M	↓ 37.82%
Investing Cash Flow	$21.4M	↓ 688.82%
Financing Cash Flow	$-6.0M	↓ 109.28%

	FY19	Y/Y Change
Operating Cash Flow	$-26.2M	↓ 12.84%
Investing Cash Flow	$-4.5M	↓ 120.85%
Financing Cash Flow	$23.3M	↓ 490.39%

	FY20	Y/Y Change
Operating Cash Flow	$-25.7M	↓ 1.78%
Investing Cash Flow	$-49.0M	↑ 1000.72%
Financing Cash Flow	$188.8M	↑ 711.37%

	FY21	Y/Y Change
Operating Cash Flow	$-37.6M	↑ 46.16%
Investing Cash Flow	$-47.9M	↓ 2.35%
Financing Cash Flow	$-4.2M	↓ 102.21%

	FY22	Y/Y Change
Operating Cash Flow	$-54.3M	↑ 44.44%
Investing Cash Flow	$33.0M	↓ 168.95%
Financing Cash Flow	$867.0K	↓ 120.78%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-7.9M	↓ 35.5%
Investing Cash Flow	$-3.2M	↓ 112.02%
Financing Cash Flow	$-852.0K	↓ 57.53%

Curis Technicals Summary

Sell

Neutral

Buy

Curis is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Curis Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Curis Inc	3.15%	-45.68%	-64.07%	-95.0%	-89.84%
Biontech Se	0.91%	36.01%	16.45%	-23.72%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.1%	-28.29%	9.42%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.05%	0.1%	86.35%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	12.05%	43.92%	95.22%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Curis Inc	NA	NA	0.0	-6.81	-3.73	-0.46	NA	3.34
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Curis Inc	Buy	$27.7M	-89.84%	NA	0.0%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

About Curis

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Organization	Curis
Employees	49
CEO	Mr. James E. Dentzer
Industry	Health Technology

Management People of Curis

Name	Title
Mr. James E. Dentzer	President, CEO, Secretary, Treasurer & Director
Ms. Diantha Duvall CPA, M.B.A.	CFO and Principal Financial & Accounting Officer
Dr. Jonathan B. Zung Ph.D.	Chief Development Officer
Mr. Mark W. Noel	Vice President of Technology Management & Intellectual Property
Dr. Robert E. Martell M.D., Ph.D.	Chief Scientific Officer
Ms. Elif McDonald	VP of Investor Relations & Corporate Communications
Dr. Reinhard Wilhelm von Roemeling M.D.	Senior Vice President of Clinical Development

Important FAQs about investing in Curis (CRIS) from India :

What is Curis share price today?

Curis share price today stands at $3.27, Open: $3.38 ; Previous Close: $3.43 ; High: $3.42 ; Low: $3.19 ; 52 Week High: $17.49 ; 52 Week Low: $2.86. The stock opens at $3.38, after a previous close of $3.43. The stock reached a daily high of $3.42 and a low of $3.19, with a 52-week high of $17.49 and a 52-week low of $2.86.

Can Indians buy Curis shares?

Yes, Indians can invest in the Curis (CRIS) from India.

With INDmoney, you can buy Curis at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Curis at zero transaction cost.

How can I buy Curis shares from India?

It is very easy to buy Curis from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Curis be purchased?

Yes, you can buy fractional shares of Curis with INDmoney app.

What are the documents required to start investing in Curis stocks?

To start investing in Curis, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.